Metvix (Methyl Aminolevulinate)

Methyl aminolevulinate acts as a prodrug that is taken up by abnormal skin cells and converted into protoporphyrin IX. When the area is illuminated with red light, the accumulated protoporphyrin IX generates reactive oxygen species, causing localized oxidative damage that selectively kills the targeted dysplastic cells while sparing surrounding healthy tissue.

The dosage and application schedule of Metvix are determined by the prescribing dermatologist based on the extent and location of the actinic keratosis lesions, the patient’s skin type, and the specific photodynamic therapy protocol used. No fixed regimen can be provided without a medical prescription.

The safety of methyl aminolevulinate in pregnancy and lactation has not been established. Because the drug is classified as a photosensitizing agent and systemic absorption is possible, it should be used only if the potential benefit justifies any potential risk to the fetus or infant.

To request Metvix, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams across international markets. After the enquiry, the sales team will verify trade or institutional credentials and respond with pricing, availability, shipping details and any required import documentation.

The most common alternative for topical photodynamic therapy is 5‑aminolevulinic acid (ALA) cream, such as Levulan. Both agents generate protoporphyrin IX, but methyl aminolevulinate typically provides deeper penetration and higher lesion‑clearance rates, especially for thicker or field‑directed treatments, while ALA may be preferred for thinner lesions or when a shorter incubation time is needed.

Metvix should be stored at ambient temperature, below 25 °C, in its original container. The packaging must be kept closed to protect the cream from moisture and direct sunlight. Do not freeze the product, and avoid exposing it to extreme temperatures that could compromise its stability.

A dermatologist applies a thin layer of Metvix cream to the affected skin area, typically covering the lesion and a small margin of surrounding tissue. After a prescribed incubation period (usually 3 hours), the area is illuminated with a red light source (approximately 635 nm) for a defined duration to activate the photosensitizer and achieve lesion clearance.

Serious adverse events include severe ulceration, secondary bacterial infection of the treated site, significant scarring, and extensive photosensitivity reactions that may persist after illumination. Patients should be monitored closely for signs of infection, excessive pain, or unexpected tissue breakdown, and any such events should be reported to a healthcare professional promptly.

Metvix is contraindicated in individuals with known porphyria, hypersensitivity to methyl aminolevulinate or any component of the formulation, and in patients with active skin infections at the treatment site. Caution is also advised for patients taking systemic photosensitizing medications or those with disorders of heme synthesis.